相似文献
1
Role of Imaging in Prostate Cancer.
PET Clin. 2009 Apr 1;4(2):135-8. doi: 10.1016/j.cpet.2009.05.003.
2
Role of multi-parametric (mp) MRI in prostate cancer.
J Pak Med Assoc. 2018 Jan;68(1):98-104.
3
Multiparametric-MRI in diagnosis of prostate cancer.
Indian J Urol. 2015 Jul-Sep;31(3):194-201. doi: 10.4103/0970-1591.159606.
4
Current role of multiparametric magnetic resonance imaging for prostate cancer.
Quant Imaging Med Surg. 2015 Oct;5(5):754-64. doi: 10.3978/j.issn.2223-4292.2015.10.08.
5
Prostate cancer managed with active surveillance: role of anatomic MR imaging and MR spectroscopic imaging.
Radiology. 2010 Jul;256(1):176-83. doi: 10.1148/radiol.10091147. Epub 2010 May 26.
6
Incorporating imaging into personalized medicine for the detection of prostate cancer: Pharmacological research-Urogenital pharmacology.
Pharmacol Res. 2016 Dec;114:163-165. doi: 10.1016/j.phrs.2016.10.020. Epub 2016 Oct 21.
7
Multiparametric prostate magnetic resonance imaging in the evaluation of prostate cancer.
CA Cancer J Clin. 2016 Jul;66(4):326-36. doi: 10.3322/caac.21333. Epub 2015 Nov 23.
8
Multiparametric magnetic resonance imaging: Current role in prostate cancer management.
Int J Urol. 2016 Jul;23(7):550-7. doi: 10.1111/iju.13119. Epub 2016 May 17.
9
Exploring the role of multimodal [F]F-PSMA-1007 PET/CT and multiparametric MRI data in predicting ISUP grading of primary prostate cancer.
Eur J Nucl Med Mol Imaging. 2025 May;52(6):2087-2095. doi: 10.1007/s00259-025-07099-0. Epub 2025 Jan 28.
10
A Pilot Study to Evaluate the Role of Magnetic Resonance Imaging for Prostate Cancer Screening in the General Population.
J Urol. 2016 Aug;196(2):361-6. doi: 10.1016/j.juro.2016.01.114. Epub 2016 Feb 13.
引用本文的文献
1
The diagnostic value of whole-body HYNIC-PSMA 11 -Tc [Tc] SPECT/CT scan in early staging of patients with moderate- and high-risk prostate cancer.
Ann Nucl Med. 2025 May 10. doi: 10.1007/s12149-025-02055-2.
2
Metabolic Differences in Glutamine Utilization Lead to Metabolic Vulnerabilities in Prostate Cancer.
Sci Rep. 2017 Nov 23;7(1):16159. doi: 10.1038/s41598-017-16327-z.
3
Influence of (11)C-choline PET/CT on radiotherapy planning in prostate cancer.
Rep Pract Oncol Radiother. 2014 Dec 16;20(2):104-12. doi: 10.1016/j.rpor.2014.11.008. eCollection 2015 Mar-Apr.
4
Characterization of primary prostate carcinoma by anti-1-amino-2-[(18)F] -fluorocyclobutane-1-carboxylic acid (anti-3-[(18)F] FACBC) uptake.
Am J Nucl Med Mol Imaging. 2013;3(1):85-96. Epub 2013 Jan 5.
5
Role of ¹¹C-choline positron emission tomography/computed tomography in evaluating patients affected by prostate cancer with suspected relapse due to prostate-specific antigen elevation.
Jpn J Radiol. 2011 Jul;29(6):394-404. doi: 10.1007/s11604-011-0570-1. Epub 2011 Jul 24.
6
Prostate cancer: PET with 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline.
J Nucl Med. 2011 Jan;52(1):81-9. doi: 10.2967/jnumed.110.077941. Epub 2010 Dec 13.
本文引用的文献
1
Bone imaging in prostate cancer.
Nat Clin Pract Urol. 2008 Aug;5(8):434-44. doi: 10.1038/ncpuro1190.
2
Prostate cancer imaging.
Acta Radiol. 2008 Feb;49(1):107-20. doi: 10.1080/02841850701545821.
3
Imaging of prostate cancer.
Curr Opin Oncol. 2007 May;19(3):259-64. doi: 10.1097/CCO.0b013e3280ad439b.
4
Imaging for prostate cancer.
Clin Oncol (R Coll Radiol). 2005 Oct;17(7):553-9. doi: 10.1016/j.clon.2005.07.003.
5
Advances in imaging in the postoperative patient with a rising prostate-specific antigen level.
Semin Oncol. 2003 Oct;30(5):616-34. doi: 10.1016/s0093-7754(03)00359-2.
6
Quantitative evaluation of bone metastases in patients with advanced prostate cancer during systemic treatment.
BJU Int. 2003 Sep;92(4):379-83; discussion 383-4. doi: 10.1046/j.1464-410x.2003.04362.x.
7
Metastatic prostate cancer: complications and treatment.
J Am Geriatr Soc. 2003 Aug;51(8):1136-42. doi: 10.1046/j.1532-5415.2003.51367.x.
8
Noninvasive detection of clinically occult lymph-node metastases in prostate cancer.
N Engl J Med. 2003 Jun 19;348(25):2491-9. doi: 10.1056/NEJMoa022749.
9
The natural history of prostate cancer.
Urol Clin North Am. 2003 May;30(2):219-26. doi: 10.1016/s0094-0143(02)00182-9.
10
Therapeutic targets for metastatic prostate cancer.
Curr Drug Targets. 2003 Apr;4(3):251-61. doi: 10.2174/1389450033491127.
Zotero 插件